search
Back to results

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

Primary Purpose

Diabetic Macular Edema

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
VEGF Trap-Eye
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Macular Edema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of diabetes mellitus (type 1 or type 2). Best corrected E-ETDRS visual acuity score of ≥ 24 letters (i.e., 20/320 or better) and ≤ 73 letters (i.e., 20/40 or worse). On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula. Retinal Thickness at the center point ≥ 250 microns. Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs. Exclusion Criteria: History of any vitreous hemorrhage within 4 weeks prior to Visit 2 (Day 1). Macular edema due to causes other than diabetic macular edema. An eye should be considered ineligible: (1) if the macular edema is considered to be related to cataract extraction or (2) clinical exam and/or OCT suggests that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema. An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal condition). An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.). Presence of any other condition or laboratory abnormality, which, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the patient's appropriate participation in this Phase 1 study.

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

VEGF Trap-Eye

Arm Description

single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1

Outcomes

Primary Outcome Measures

To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME)

Secondary Outcome Measures

To obtain a preliminary assessment of the effect of a single dose of VEGF Trap-Eye on central retinal thickness (CRT) at the center point as determined by optical coherence tomography (OCT)
To obtain a preliminary assessment of the effect of a single IVT administration of VEGF Trap-Eye on visual acuity

Full Information

First Posted
April 28, 2006
Last Updated
June 8, 2011
Sponsor
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00320814
Brief Title
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
Official Title
An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap in Patients With Diabetic Macular Edema
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Regeneron Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
Detailed Description
This is an open label study. Initially, 5 patients with DME will receive an ITV injection of VEGF Trap into the study eye. Additional patients may be enrolled at the same or additional dose levels. Patients will be observed for six weeks following the injection for assessments of ocular and systemic safety.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VEGF Trap-Eye
Arm Type
Experimental
Arm Description
single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
Intervention Type
Drug
Intervention Name(s)
VEGF Trap-Eye
Intervention Description
single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
Primary Outcome Measure Information:
Title
To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME)
Time Frame
Assessments for safety and tolerablity are performed at each visit (Visit 1 - Visit 10)
Secondary Outcome Measure Information:
Title
To obtain a preliminary assessment of the effect of a single dose of VEGF Trap-Eye on central retinal thickness (CRT) at the center point as determined by optical coherence tomography (OCT)
Time Frame
Assessments for CRT are performed at each visit (Visit 1 - Visit 10) by means of OCT.
Title
To obtain a preliminary assessment of the effect of a single IVT administration of VEGF Trap-Eye on visual acuity
Time Frame
Assessments for visual acuity are performed at each visit (Visit 1 - Visit 10).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of diabetes mellitus (type 1 or type 2). Best corrected E-ETDRS visual acuity score of ≥ 24 letters (i.e., 20/320 or better) and ≤ 73 letters (i.e., 20/40 or worse). On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula. Retinal Thickness at the center point ≥ 250 microns. Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs. Exclusion Criteria: History of any vitreous hemorrhage within 4 weeks prior to Visit 2 (Day 1). Macular edema due to causes other than diabetic macular edema. An eye should be considered ineligible: (1) if the macular edema is considered to be related to cataract extraction or (2) clinical exam and/or OCT suggests that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema. An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal condition). An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.). Presence of any other condition or laboratory abnormality, which, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the patient's appropriate participation in this Phase 1 study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Avner Ingerman, MD
Organizational Affiliation
Regeneron Pharmaceuticals
Official's Role
Study Director
Facility Information:
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28210
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

We'll reach out to this number within 24 hrs